Background/Objectives: Anaplastic lymphoma kinase (ALK)-positive (+) anaplastic large cell lymphoma (ALCL) is known to express CD25, but its significance has not been well studied. Methods: In the present study, we identified 54 ALK+ ALCL patients with CD25 results available and investigated the significance of CD25 expression levels. Results: Forty-two (78%) cases had high CD25 expressions, whereas low CD25 expressions were found in 12 (22%) cases. Compared with ALK+ ALCL patients with CD25-high neoplasms, patients with CD25-low neoplasms were older (median: 40 years vs. 29 years,p= 0.01) and more often had thrombocytopenia (40% vs. 0%,p= 0.02). Between CD25-low and CD25-high groups, other clinical features were similar to each other (allp> 0.05). CD25-low ALK+ ALCL cases showed higher frequency of surface CD3 (100% vs. 3%,p= 0.001) and CD8 (57% vs. 14%,p= 0.03). Fourteen of 47 (30%) ALK+ ALCL patients died (median follow-up time, 33.8 months; range, 0.3–382.8 months): 5 of 9 (56%) patients with CD25-low neoplasms and 9 of 38 (24%) patients with CD25-high neoplasms. Univariate analysis showed: (1) the OS of patients with CD25-low ALK+ ALCL was shorter than that of patients with CD25-high ALK+ ALCL (median: 72.2 months vs. undefined,p= 0.02); and (2) young (<30 years) patients with high CD25 expression had the best prognosis, with a long-term OS rate of 89%. However, in multivariate analysis, low CD25 expression did not significantly impact OS. Conclusions: most cases of ALK+ ALCL highly express CD25 which is a potential target for therapy. ALK+ ALCL with low CD25 expression is associated with older patient age and increased frequency of thrombocytopenia and surface CD3 and CD8 expression.
背景/目的：已知间变性淋巴瘤激酶（ALK）阳性（+）间变性大细胞淋巴瘤（ALCL）表达CD25，但其临床意义尚未得到充分研究。方法：本研究纳入54例具有CD25检测结果的ALK+ ALCL患者，探讨CD25表达水平的临床意义。结果：42例（78%）患者呈现高CD25表达，12例（22%）为低CD25表达。与CD25高表达组相比，CD25低表达组患者年龄更大（中位年龄：40岁 vs. 29岁，p=0.01），血小板减少症发生率更高（40% vs. 0%，p=0.02）。两组其他临床特征无显著差异（均p>0.05）。CD25低表达组表现出更高的表面CD3（100% vs. 3%，p=0.001）和CD8（57% vs. 14%，p=0.03）表达频率。47例患者中14例（30%）死亡（中位随访时间33.8个月，范围0.3-382.8个月）：CD25低表达组9例中5例（56%）死亡，CD25高表达组38例中9例（24%）死亡。单因素分析显示：（1）CD25低表达组总生存期短于高表达组（中位生存期：72.2个月 vs. 未达到，p=0.02）；（2）CD25高表达的年轻（<30岁）患者预后最佳，长期总生存率达89%。但多因素分析显示CD25低表达对总生存期无显著影响。结论：大多数ALK+ ALCL病例高表达CD25，这使其成为潜在治疗靶点。CD25低表达的ALK+ ALCL与患者高龄、血小板减少症发生率增高及表面CD3/CD8表达增加相关。
肿瘤(癌症)患者之家